{
  "id": 916608,
  "title": "Avicanna Reports Q2 2026 Financial Results",
  "url": "https://urgent.news/2026/08/14/avicanna-reports-q2-2026-financial-results",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-14T22:31:15.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/avicanna-reports-q2-2026-financial-results"
  },
  "original_language": "en",
  "account": null,
  "summary": "Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product salesQUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}